vs
Side-by-side financial comparison of BWX Technologies, Inc. (BWXT) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
BWX Technologies, Inc. is the larger business by last-quarter revenue ($885.8M vs $622.0M, roughly 1.4× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 10.5%, a 23.9% gap on every dollar of revenue. On growth, BWX Technologies, Inc. posted the faster year-over-year revenue change (18.7% vs 4.8%). Over the past eight quarters, BWX Technologies, Inc.'s revenue compounded faster (21.1% CAGR vs 4.6%).
BWX Technologies, Inc. is a company headquartered in Lynchburg, Virginia that supplies nuclear components and fuel internationally.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
BWXT vs RPRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $885.8M | $622.0M |
| Net Profit | $93.0M | $214.2M |
| Gross Margin | — | — |
| Operating Margin | 10.4% | 62.4% |
| Net Margin | 10.5% | 34.4% |
| Revenue YoY | 18.7% | 4.8% |
| Net Profit YoY | 30.9% | 2.9% |
| EPS (diluted) | $1.02 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $885.8M | $622.0M | ||
| Q3 25 | $866.3M | $609.3M | ||
| Q2 25 | $764.0M | $578.7M | ||
| Q1 25 | $682.3M | $568.2M | ||
| Q4 24 | $746.3M | $593.6M | ||
| Q3 24 | $672.0M | $564.7M | ||
| Q2 24 | $681.5M | $537.3M | ||
| Q1 24 | $604.0M | $568.0M |
| Q4 25 | $93.0M | $214.2M | ||
| Q3 25 | $82.1M | $288.2M | ||
| Q2 25 | $78.4M | $30.2M | ||
| Q1 25 | $75.5M | $238.3M | ||
| Q4 24 | $71.0M | $208.2M | ||
| Q3 24 | $69.5M | $544.0M | ||
| Q2 24 | $73.0M | $102.0M | ||
| Q1 24 | $68.5M | $4.8M |
| Q4 25 | — | — | ||
| Q3 25 | 21.8% | — | ||
| Q2 25 | 25.1% | — | ||
| Q1 25 | 24.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 24.4% | — | ||
| Q2 24 | 24.7% | — | ||
| Q1 24 | 24.6% | — |
| Q4 25 | 10.4% | 62.4% | ||
| Q3 25 | 13.1% | 70.1% | ||
| Q2 25 | 13.4% | 36.3% | ||
| Q1 25 | 14.2% | 94.0% | ||
| Q4 24 | 12.4% | 60.9% | ||
| Q3 24 | 14.4% | — | ||
| Q2 24 | 14.5% | 50.2% | ||
| Q1 24 | 15.4% | -13.0% |
| Q4 25 | 10.5% | 34.4% | ||
| Q3 25 | 9.5% | 47.3% | ||
| Q2 25 | 10.3% | 5.2% | ||
| Q1 25 | 11.1% | 41.9% | ||
| Q4 24 | 9.5% | 35.1% | ||
| Q3 24 | 10.3% | 96.3% | ||
| Q2 24 | 10.7% | 19.0% | ||
| Q1 24 | 11.3% | 0.8% |
| Q4 25 | $1.02 | $0.49 | ||
| Q3 25 | $0.89 | $0.67 | ||
| Q2 25 | $0.85 | $0.07 | ||
| Q1 25 | $0.82 | $0.55 | ||
| Q4 24 | $0.77 | $0.46 | ||
| Q3 24 | $0.76 | $1.21 | ||
| Q2 24 | $0.79 | $0.23 | ||
| Q1 24 | $0.75 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $499.8M | $618.7M |
| Total DebtLower is stronger | — | $9.0B |
| Stockholders' EquityBook value | $1.2B | $9.7B |
| Total Assets | $4.3B | $19.6B |
| Debt / EquityLower = less leverage | — | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $499.8M | $618.7M | ||
| Q3 25 | $79.6M | $938.9M | ||
| Q2 25 | $37.0M | $631.9M | ||
| Q1 25 | $55.4M | $1.1B | ||
| Q4 24 | $74.1M | $929.0M | ||
| Q3 24 | $35.5M | $950.1M | ||
| Q2 24 | $48.3M | $1.8B | ||
| Q1 24 | $45.9M | $843.0M |
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
| Q4 25 | $1.2B | $9.7B | ||
| Q3 25 | $1.2B | $9.6B | ||
| Q2 25 | $1.2B | $9.5B | ||
| Q1 25 | $1.1B | $9.8B | ||
| Q4 24 | $1.1B | $10.3B | ||
| Q3 24 | $1.1B | $10.3B | ||
| Q2 24 | $998.5M | $9.8B | ||
| Q1 24 | $946.2M | $9.9B |
| Q4 25 | $4.3B | $19.6B | ||
| Q3 25 | $3.8B | $19.3B | ||
| Q2 25 | $3.7B | $18.3B | ||
| Q1 25 | $3.1B | $17.6B | ||
| Q4 24 | $2.9B | $18.2B | ||
| Q3 24 | $2.9B | $18.0B | ||
| Q2 24 | $2.8B | $17.7B | ||
| Q1 24 | $2.8B | $16.1B |
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $127.0M | $827.1M |
| Free Cash FlowOCF − Capex | $56.8M | — |
| FCF MarginFCF / Revenue | 6.4% | — |
| Capex IntensityCapex / Revenue | 7.9% | — |
| Cash ConversionOCF / Net Profit | 1.37× | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | $295.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $127.0M | $827.1M | ||
| Q3 25 | $143.2M | $702.6M | ||
| Q2 25 | $159.0M | $364.0M | ||
| Q1 25 | $50.6M | $596.1M | ||
| Q4 24 | $276.9M | $742.5M | ||
| Q3 24 | $32.6M | $703.6M | ||
| Q2 24 | $65.9M | $658.2M | ||
| Q1 24 | $33.0M | $664.6M |
| Q4 25 | $56.8M | — | ||
| Q3 25 | $94.9M | — | ||
| Q2 25 | $126.3M | — | ||
| Q1 25 | $17.3M | — | ||
| Q4 24 | $224.4M | — | ||
| Q3 24 | $-7.7M | — | ||
| Q2 24 | $35.5M | — | ||
| Q1 24 | $2.6M | — |
| Q4 25 | 6.4% | — | ||
| Q3 25 | 11.0% | — | ||
| Q2 25 | 16.5% | — | ||
| Q1 25 | 2.5% | — | ||
| Q4 24 | 30.1% | — | ||
| Q3 24 | -1.1% | — | ||
| Q2 24 | 5.2% | — | ||
| Q1 24 | 0.4% | — |
| Q4 25 | 7.9% | — | ||
| Q3 25 | 5.6% | — | ||
| Q2 25 | 4.3% | — | ||
| Q1 25 | 4.9% | — | ||
| Q4 24 | 7.0% | — | ||
| Q3 24 | 6.0% | — | ||
| Q2 24 | 4.5% | — | ||
| Q1 24 | 5.0% | — |
| Q4 25 | 1.37× | 3.86× | ||
| Q3 25 | 1.74× | 2.44× | ||
| Q2 25 | 2.03× | 12.06× | ||
| Q1 25 | 0.67× | 2.50× | ||
| Q4 24 | 3.90× | 3.57× | ||
| Q3 24 | 0.47× | 1.29× | ||
| Q2 24 | 0.90× | 6.45× | ||
| Q1 24 | 0.48× | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BWXT
| Nuclear Component Program | $436.4M | 49% |
| Nuclear Manufacturing | $134.8M | 15% |
| Cost Plus Fee | $116.1M | 13% |
| Uranium And Nuclear Services | $103.8M | 12% |
| Commercial Operations | $49.0M | 6% |
| Commercial Operations Segment | $33.7M | 4% |
| Transferred At Point In Time | $1.3M | 0% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
